[{"indications": "Indications\u00a0hypertension (but see notes above); symptomatic\r\nheart failure (adjunct\u2014\n(From 2.5.5 Drugs affecting the renin-angiotensin system: British National Formulary)\n2.5.5 Drugs affecting the renin-angiotensin system); short-term\r\ntreatment following myocardial infarction in haemodynamically stable\r\npatients; renal complications of diabetes mellitus", "name": "LISINOPRIL", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.5 Hypertension and heart failure", "2.5.5 Drugs affecting the renin-angiotensin system", "2.5.5.1 Angiotensin-converting enzyme inhibitors", "LISINOPRIL"], "cautions": "Cautions\u00a0\n(From 2.5.5.1 Angiotensin-converting enzyme inhibitors: British National Formulary)\nCautions\u00a0ACE inhibitors need to be initiated with care in patients receiving diuretics (important: see Concomitant diuretics, below); first doses can cause hypotension especially in patients taking high doses of diuretics, on a low-sodium diet, on dialysis, dehydrated, or with heart failure (see above). They should also be used with caution in peripheral vascular disease or generalised atherosclerosis owing to risk of clinically silent renovascular disease; for use in pre-existing renovascular disease, see Renal Effects above. The risk of agranulocytosis is possibly increased in collagen vascular disease (blood counts recommended). ACE inhibitors should be used with care in patients with severe or symptomatic aortic stenosis (risk of hypotension) and in hypertrophic cardiomyopathy. They should also be used with care (or avoided) in those with a history of idiopathic or hereditary angioedema. If jaundice or marked elevations of hepatic enzymes occur during treatment then the ACE inhibitor should be discontinued\u2014risk of hepatic necrosis (see also Hepatic impairment, below). Interactions: Appendix 1 (ACE inhibitors).Anaphylactoid reactions\u00a0To prevent anaphylactoid reactions, ACE inhibitors should be avoided during dialysis with high-flux polyacrylonitrile membranes and during low-density lipoprotein apheresis with dextran sulphate; they should also be withheld before desensitisation with wasp or bee venom.Concomitant diuretics\u00a0ACE inhibitors can cause a very rapid fall in blood pressure in volume-depleted patients; treatment should therefore be initiated with very low doses. If the dose of diuretic is greater than 80\u00a0mg furosemide or equivalent, the ACE inhibitor should be initiated under close supervision and in some patients the diuretic dose may need to be reduced or the diuretic discontinued at least 24\u00a0hours beforehand (may not be possible in heart failure\u2014risk of pulmonary oedema). If high-dose diuretic therapy cannot be stopped, close observation is recommended after administration of the first dose of ACE inhibitor, for at least 2 hours or until the blood pressure has stabilised.", "side-effects": "Side-effects\u00a0see notes above; also less commonly tachycardia, palpitation, cerebrovascular accident, myocardial infarction,\r\nRaynaud\u2019s syndrome, confusion, mood changes, vertigo, sleep disturbances,\r\nasthenia, impotence; rarely dry mouth, gynaecomastia,\r\nalopecia, psoriasis; very rarely allergic alveolitis,\r\npulmonary infiltrates, profuse sweating, pemphigus, Stevens-Johnson\r\nsyndrome, and toxic epidermal necrolysis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/119720.htm", "doses": ["Hypertension, initially 10\u00a0mg once daily; if used in addition\r\nto diuretic (see notes above) or\r\nin cardiac decompensation or in volume depletion, initially 2.5\u20135\u00a0mg\r\nonce daily; usual maintenance dose 20\u00a0mg once daily; max. 80\u00a0mg once\r\ndaily", "Heart failure (adjunct), initially 2.5\u00a0mg once daily under close\r\nmedical supervision (see notes above);\r\nincreased in steps no greater than 10\u00a0mg at intervals of at least\r\n2 weeks up to max. 35\u00a0mg once daily if tolerated", "Prophylaxis after myocardial infarction, systolic blood pressure\r\nover 120\u00a0mmHg, 5\u00a0mg within 24 hours, followed by further 5\u00a0mg 24 hours\r\nlater, then 10\u00a0mg after a further 24 hours, and continuing with 10\u00a0mg\r\nonce daily for 6 weeks (or continued if heart failure); systolic blood\r\npressure 100\u2013120\u00a0mmHg, initially 2.5\u00a0mg once daily, increased to maintenance\r\ndose of 5\u00a0mg once daily", "Should not be started after\r\nmyocardial infarction if systolic blood pressure less than 100\u00a0mmHg; temporarily reduce maintenance dose to 5\u00a0mg and if necessary 2.5\u00a0mg\r\ndaily if systolic blood pressure 100\u00a0mmHg or less during treatment;\r\nwithdraw if prolonged hypotension occurs (systolic blood pressure\r\nless than 90\u00a0mmHg for more than 1 hour)", "Renal complications of diabetes mellitus, initially 2.5\u20135\u00a0mg\r\nonce daily adjusted according to response; usual dose range 10\u201320\u00a0mg\r\nonce daily"], "pregnancy": "Pregnancy\u00a0\n(From 2.5.5.1 Angiotensin-converting enzyme inhibitors: British National Formulary)\nPregnancy\u00a0ACE inhibitors should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohydramnios have also been reported."}, {"indications": "Indications\u00a0hypertension (but see notes above); symptomatic\r\nheart failure (adjunct\u2014\n(From 2.5.5 Drugs affecting the renin-angiotensin system: British National Formulary)\n2.5.5 Drugs affecting the renin-angiotensin system); short-term\r\ntreatment following myocardial infarction in haemodynamically stable\r\npatients; renal complications of diabetes mellitus", "name": "LISINOPRIL With diuretic", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.5 Hypertension and heart failure", "2.5.5 Drugs affecting the renin-angiotensin system", "2.5.5.1 Angiotensin-converting enzyme inhibitors", "LISINOPRIL", "With diuretic"], "cautions": "Cautions\u00a0\n(From 2.5.5.1 Angiotensin-converting enzyme inhibitors: British National Formulary)\nCautions\u00a0ACE inhibitors need to be initiated with care in patients receiving diuretics (important: see Concomitant diuretics, below); first doses can cause hypotension especially in patients taking high doses of diuretics, on a low-sodium diet, on dialysis, dehydrated, or with heart failure (see above). They should also be used with caution in peripheral vascular disease or generalised atherosclerosis owing to risk of clinically silent renovascular disease; for use in pre-existing renovascular disease, see Renal Effects above. The risk of agranulocytosis is possibly increased in collagen vascular disease (blood counts recommended). ACE inhibitors should be used with care in patients with severe or symptomatic aortic stenosis (risk of hypotension) and in hypertrophic cardiomyopathy. They should also be used with care (or avoided) in those with a history of idiopathic or hereditary angioedema. If jaundice or marked elevations of hepatic enzymes occur during treatment then the ACE inhibitor should be discontinued\u2014risk of hepatic necrosis (see also Hepatic impairment, below). Interactions: Appendix 1 (ACE inhibitors).Anaphylactoid reactions\u00a0To prevent anaphylactoid reactions, ACE inhibitors should be avoided during dialysis with high-flux polyacrylonitrile membranes and during low-density lipoprotein apheresis with dextran sulphate; they should also be withheld before desensitisation with wasp or bee venom.Concomitant diuretics\u00a0ACE inhibitors can cause a very rapid fall in blood pressure in volume-depleted patients; treatment should therefore be initiated with very low doses. If the dose of diuretic is greater than 80\u00a0mg furosemide or equivalent, the ACE inhibitor should be initiated under close supervision and in some patients the diuretic dose may need to be reduced or the diuretic discontinued at least 24\u00a0hours beforehand (may not be possible in heart failure\u2014risk of pulmonary oedema). If high-dose diuretic therapy cannot be stopped, close observation is recommended after administration of the first dose of ACE inhibitor, for at least 2 hours or until the blood pressure has stabilised.", "side-effects": "Side-effects\u00a0see notes above; also less commonly tachycardia, palpitation, cerebrovascular accident, myocardial infarction,\r\nRaynaud\u2019s syndrome, confusion, mood changes, vertigo, sleep disturbances,\r\nasthenia, impotence; rarely dry mouth, gynaecomastia,\r\nalopecia, psoriasis; very rarely allergic alveolitis,\r\npulmonary infiltrates, profuse sweating, pemphigus, Stevens-Johnson\r\nsyndrome, and toxic epidermal necrolysis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2596.htm", "doses": ["Hypertension, initially 10\u00a0mg once daily; if used in addition\r\nto diuretic (see notes above) or\r\nin cardiac decompensation or in volume depletion, initially 2.5\u20135\u00a0mg\r\nonce daily; usual maintenance dose 20\u00a0mg once daily; max. 80\u00a0mg once\r\ndaily", "Heart failure (adjunct), initially 2.5\u00a0mg once daily under close\r\nmedical supervision (see notes above);\r\nincreased in steps no greater than 10\u00a0mg at intervals of at least\r\n2 weeks up to max. 35\u00a0mg once daily if tolerated", "Prophylaxis after myocardial infarction, systolic blood pressure\r\nover 120\u00a0mmHg, 5\u00a0mg within 24 hours, followed by further 5\u00a0mg 24 hours\r\nlater, then 10\u00a0mg after a further 24 hours, and continuing with 10\u00a0mg\r\nonce daily for 6 weeks (or continued if heart failure); systolic blood\r\npressure 100\u2013120\u00a0mmHg, initially 2.5\u00a0mg once daily, increased to maintenance\r\ndose of 5\u00a0mg once daily", "Should not be started after\r\nmyocardial infarction if systolic blood pressure less than 100\u00a0mmHg; temporarily reduce maintenance dose to 5\u00a0mg and if necessary 2.5\u00a0mg\r\ndaily if systolic blood pressure 100\u00a0mmHg or less during treatment;\r\nwithdraw if prolonged hypotension occurs (systolic blood pressure\r\nless than 90\u00a0mmHg for more than 1 hour)", "Renal complications of diabetes mellitus, initially 2.5\u20135\u00a0mg\r\nonce daily adjusted according to response; usual dose range 10\u201320\u00a0mg\r\nonce daily", "Name[Zestoretic\u00ae (AstraZeneca) ] Zestoretic 10 tablets, peach, lisinopril (as dihydrate) 10\u00a0mg, hydrochlorothiazide 12.5\u00a0mg, net price 28-tab pack = \u00a32.27\nZestoretic 20 tablets, lisinopril (as dihydrate) 20\u00a0mg, hydrochlorothiazide 12.5\u00a0mg, net price 28-tab pack = \u00a33.84"], "pregnancy": "Pregnancy\u00a0\n(From 2.5.5.1 Angiotensin-converting enzyme inhibitors: British National Formulary)\nPregnancy\u00a0ACE inhibitors should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohydramnios have also been reported."}]